Daily Health Headlines

Drug Shows Promise Against MS in Mouse Study

👤by Mary Elizabeth Dallas 0 comments 🕔Thursday, September 22nd, 2016

WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- An experimental drug, laquinimod, appears to prevent or slow the progression of multiple sclerosis (MS) in mice, according to a new study.

"This study has given us more insight into how laquinimod works," said study author Dr. Scott Zamvil, of the University of California, San Francisco. "But because this was an animal study, more research needs to be done before we know if it could have similar results in people."

Still, "these results are promising because they provide hope for people with progressive MS, an advanced version of the disease for which there is currently no treatment," Zamvil said in a news release from the American Academy of Neurology.

A healthy immune system has T cells and B cells that help the body prevent infections. However, for people with MS, these cells create antibodies that attack and destroy the protective outer coating (myelin) that surrounds nerves in the brain and spinal cord.

In the new study, Zamvil's team used 50 mice bred to develop a spontaneous form of MS. The mice received either a daily dose of oral laquinimod, or a placebo (water). The investigators then analyzed and counted the rodents' T cells and B cells.

Only 29 percent of the mice taking laquinimod developed MS compared to 58 percent of those given the placebo, the study found.

The researchers believe that the drug may help prevent MS, since there was a 96 percent reduction in harmful clusters of B cells -- which are only found in people with MS.

In a second experiment that involved 22 mice, Zamvil's group gave the animals laquinimod after they had experienced some MS-linked paralysis. The disease progression among the mice slowed significantly as a result, the findings showed.

Dr. Paul Wright is chair of neurology at North Shore University Hospital in Manhasset, N.Y. He reviewed the new findings and agreed that laquinimod "may provide a neuroprotective effect."

Wright said that "this is a very promising study and provides us with insight into a novel medication that may have benefit for patients with this devastating disease." However, the research was "performed in mice, and human studies need to be performed to confirm the effects and ensure human tolerability of the medication," he added.

The study was published online Sept. 21 in the journal Neurology, Neuroimmunology & Neuroinflammation.

-- Mary Elizabeth Dallas

Article Credits / Source

Mary Elizabeth Dallas / HealthDay

Mary Elizabeth Dallas wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCES: Paul Wright, M.D., chair, neurology, North Shore University Hospital, Manhasset, and Long Island Jewish Medical Center, New Hyde Park, N.Y.; American Academy of Neurology, news release, Sept. 21, 2016

View More Articles From Mary Elizabeth Dallas 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Neurology Articles

Moms' Rheumatoid Arthritis May Be Linked to Epilepsy Risk in Kids

Moms' Rheumatoid Arthritis May Be Linked to Epilepsy Risk in Kids0

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- Some children born to mothers with rheumatoid arthritis may have higher-than-average odds of developing epilepsy, a new study suggests. Children born to mothers with rheumatoid arthritis were ...

Brain Implant Lets 'Locked-In' ALS Patient Communicate

Brain Implant Lets 'Locked-In' ALS Patient Communicate0

MONDAY, Nov. 14, 2016 (HealthDay News) -- A high-tech implant has enabled a paralyzed woman with late-stage ALS (amyotrophic lateral sclerosis) to communicate through brain signaling, researchers say. The degenerative disease robbed Hanneke De ...

Blood Test May Someday Diagnose Concussion

Blood Test May Someday Diagnose Concussion0

FRIDAY, Nov. 11, 2016 (HealthDay News) -- A simple blood test may one day diagnose concussions with more than 90 percent certainty, a small Canadian study suggests. This new test is unique, the authors said, because it looks for more than 100 ...

gabapentin (Neurontin, Gralise, Horizant, Fanatrex FusePag)

gabapentin (Neurontin, Gralise, Horizant, Fanatrex FusePag)0

home / neurology center / neurology a-z list / gabapentin index / gabapentin (neurontin, gralise, horizant, fanatrex fusepag) drug monograph Pharmacy Author: Omudhome Ogbru, PharmD Omudhome Ogbru, ...

MS Symptoms May Develop Earlier in Darker, Cooler Climes

MS Symptoms May Develop Earlier in Darker, Cooler Climes0

THURSDAY, Nov. 3, 2016 (HealthDay News) -- The farther from the Equator someone with multiple sclerosis lives, the earlier symptoms begin, a new study finds. MS is a progressive disease affecting the central nervous system. Although symptoms ...

View More Neurology Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!